Borosil Scientific Shares Zoom 20% as Q3 Profit Surges 102% YoY to ₹9 Crore, Revenue Up 20%

Borosil Scientific shares jumped nearly 20% in early trade on February 12, 2026, after the company reported strong third-quarter earnings that surprised the market. The stock touched an intraday high of ₹126.60, reflecting renewed investor confidence. 

The rally followed a sharp 102% year-on-year jump in net profit to around ₹9 crore, while revenue climbed about 20% to ₹121 crore. These numbers signaled better cost control, higher demand, and improved margins. Traders reacted fast, pushing volumes sharply higher within minutes of the results. 

For investors tracking mid-cap opportunities, Borosil Scientific’s performance has suddenly become hard to ignore. The strong earnings momentum, combined with growing demand from pharma and research labs, has turned this stock into one of today’s most talked-about market movers.

Borosil Scientific Q3 FY26 Financial Highlights: What the Numbers Say?

Borosil Scientific reported strong results for the quarter ended December 31, 2025 (Q3 FY26), surprising markets and driving a sharp stock rally. Consolidated net profit surged ~102% year‑on‑year to ₹8.68 crore, compared with ₹4.30 crore in the same quarter last year. Revenue from operations grew 19.57% YoY to ₹121.30 crore, up from ₹101.45 crore in Q3 FY25. 

EBITDA rose 71.83% to ₹17 crore, while EBITDA margins improved to 14.18% from 9.89%. These results reveal both topline growth and improved operating efficiency. Borosil Scientific’s market cap stood at around ₹1,100 crore as of February 12, 2026, reflecting strong investor interest following the earnings release.

Why Did Borosil Scientific Shares Surge?

The immediate jump in Borosil Scientific shares, rallying up to 20% intraday on February 12, 2026, was directly tied to the Q3 earnings beat. As of late morning trading, the stock was up over 17%, continuing gains seen in the prior week and month. 

The surge came after the company posted strong YoY profit and revenue growth, coupled with expanding margins and better segment performance. Investors also reacted positively to improved confidence around demand from pharma labs and industrial research sectors, which are core revenue drivers.

What Is the Current Stock Position? Live Data & Technical Signals 

According to Meyka’s stock dashboard, investors tracking Borosil Scientific (ticker: BOROSCI.NS) noted a price uptick tied to the earnings release and volume activity. Technical indicators often included in Meyka analysis help explain short‑term stock movement, but should be read with context from fundamentals.

From other market data, Borosil Scientific’s share price was trading around ₹126-₹127 after the earnings news, well above the 52‑week low of ~₹99.53 seen in January 2026, though still below prior highs near ₹190.79 last year. Technical charts show mixed signals, with short‑term momentum supportive but longer‑term indicators (like 100–200 day moving averages) hinting at broader volatility.

Which of Borosil Scientific’s Segments Drove Growth in Q3 FY26? 

Borosil Scientific’s revenue growth came from multiple business verticals:

Scientific Laboratory Glass & Equipment

• Growth in demand from pharma quality control labs and research institutions supported this segment.
• Reported revenues here were higher, contributing significantly to overall topline growth.

#EarningsWithETNOW | Given the largely flat Q3 topline, how much impact did seasonality have on revenues, and what is the visibility on Borosil’s FY26 growth outlook?

Shreevar Kheruka of Borosil on how BES regulations disrupted insulated bottle supply chains, while the company… pic.twitter.com/TkREf43OMW

— ET NOW (@ETNOWlive) February 10, 2026

Glassware & Process Systems

• The glassware vertical also saw solid expansion, with demand from packaging and process sciences boosting sales.
• Both segments outpaced mediocre market performance in related industrial categories.

Improved margins suggest better cost management and a shift toward higher‑value product lines.

What Do Analysts Say? Fundamentals vs Market Performance

Analyst views on Borosil Scientific are mixed:

• Fundamental data shows a low return on equity (ROE) and modest capital efficiency, reflected in sub‑industry average returns. This raises caution about long‑term profit sustainability.
• The P/E ratio remains elevated, indicating market expectations of future growth are priced into the current valuation.
• Short‑term technical analysis suggests possible buy interest, but also signals volatility and mixed trend strength. Variations in RSI and moving averages reflect this.

An AI stock analysis tool integrated into many platforms often highlights such divergences between technical momentum and fundamental health, helping traders balance short‑term opportunity with long‑term risk.

Is Borosil Scientific a Buy After the Rally? Analyst Insights 

Investors and analysts are asking whether the stock’s sharp gain is justified:

Bullish Factors

• Strong Q3 earnings and margin expansion.
• Growth in core lab and pharma demand.
• Net profit recovery after earlier weak quarters.

Cautionary Notes

• Broader financial metrics show modest ROE and capital efficiency.
• Stock remains below prior highs, signaling longer‑term pressure.
• Elevated valuation compared to earnings history.

Most forecasts from high‑authority stock forecasters note that Borosil Scientific’s price movement will depend on continued quarterly performance consistency and broader sector demand.

Conclusion: What Investors Should Watch Next 

Borosil Scientific’s Q3 FY26 results showed strong profit and revenue growth. The 20% stock rise on February 12, 2026, reflects investor interest, but volatility remains. Watch Q4 earnings, segment demand, and margins before investing.

Frequently Asked Questions (FAQs)

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.